Lumera's Revenues Fall 44 Percent as It Shuts Down Plexera's Operations | GenomeWeb
NEW YORK (GenomeWeb News) – Lumera reported after the close of the market yesterday that its first-quarter revenues fell 44 percent and its net loss rose 124 percent as the company has stopped making investments in its Plexera Bioscience proteomics business. 
Lumera said in its earnings report that it had revenues of $484,000 for the three-month period ended March 31, 2008, compared to revenues of $860,000 in the first quarter of 2007.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.